Abstract
Objective To investigate the prevalence of bias attributable to composite outcome (BACO) in clinical trials.
Study design and setting We searched PubMed for randomized clinical trials where the primary outcome was a binary composite that included all-cause mortality among its components from January 1, 2019, to December 31, 2020. For each trial, the BACO index was calculated to assess the correspondence between effects on the composite outcome and that on mortality. This systematic review was registered in PROSPERO (CRD42021229554).
Results After screening 1,076 citations and 171 full-text articles, 91 studies were included from 13 different medical areas. The prevalence of significant or suggestive BACO among the 91 included articles was 25.2% (n=23), including 12 with p<0.005 and 11 with p between 0.005 and <0.05. We observed that in 17 (73.9%) of these 23 studies, the BACO index value was between zero and <1, indicating an underestimation of the effect. The other six studies showed negative values (26.1%), indicating an inversion of the association with mortality. None of the studies showed significant overestimation of the association attributable to the composite outcome.
Conclusion These findings highlight the need to predefine guidelines for interpreting effects on composite endpoints based on objective criteria such as the BACO index.
Key Findings
The study found that 25.2% of the included clinical trials exhibited significant or suggestive bias attributable to composite outcomes (BACO).
In 73.9% of these cases, the BACO index was less than 1, indicating an underestimation of the effect. 26.1% of the studies showed an inversion of the association with mortality.
No significant overestimation of the association due to composite outcomes was observed.
What This Adds to What Was Known?
This study contributes to the existing knowledge by quantifying the prevalence of bias attributable to composite outcomes in clinical trials.
It highlights that a significant proportion of trials may underestimate the effect or even show an inversion of the association with mortality when composite outcomes are used.
This finding emphasizes the need for careful consideration and objective criteria, like the BACO index, in the design and interpretation of clinical trials involving composite outcomes.
What Is the Implication and What Should Change Now?
Researchers and clinicians should be cautious about relying solely on composite outcomes without assessing the potential biases they introduce.
The study suggests a need for predefined guidelines and objective criteria, such as the BACO index, for interpreting the effects of composite outcomes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
